Prudential Financial
FATE icon

Prudential Financial’s Fate Therapeutics FATE Stock Holding History

Prudential Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.6K Buy
26,330
+3,170
+14% +$3.86K ﹤0.01% 2358
2025
Q4 		$22.8K Sell
23,160
-20,031
-46% -$24.1K ﹤0.01% 2192
2025
Q3 		$54.4K Buy
43,191
+21,400
+98% +$23.1K ﹤0.01% 2329
2025
Q2 		$24.4K Sell
21,791
-51,500
-70% -$59.9K ﹤0.01% 2391
2025
Q1 		$57.9K Sell
73,291
-248,110
-77% -$304K ﹤0.01% 2182
2024
Q4 		$530K Sell
321,401
-35,200
-10% -$88.7K ﹤0.01% 1809
2024
Q3 		$1.25M Buy
356,601
+500
+0.1% +$1.95K ﹤0.01% 1768
2024
Q2 		$1.17M Sell
356,101
-27,100
-7% -$119K ﹤0.01% 1738
2024
Q1 		$2.81M Sell
383,201
-176,810
-32% -$1.09M ﹤0.01% 1246
2023
Q4 		$2.09M Buy
560,011
+365,100
+187% +$862K ﹤0.01% 1406
2023
Q3 		$413K Buy
194,911
+128,600
+194% +$426K ﹤0.01% 2141
2023
Q2 		$316K Sell
66,311
-93,600
-59% -$517K ﹤0.01% 2282
2023
Q1 		$911K Buy
+159,911
New +$965K ﹤0.01% 1795
2022
Q2 		– Sell
-6,766
Closed -$262K – 2695
2022
Q1 		$262K Sell
6,766
-62
-0.9% -$2.4K ﹤0.01% 2448
2021
Q4 		$408K Sell
6,828
-66,188
-91% -$3.75M ﹤0.01% 2281
2021
Q3 		$4.42M Sell
73,016
-1,514
-2% -$119K 0.01% 1046
2021
Q2 		$6.47M Buy
74,530
+9,555
+15% +$770K 0.01% 927
2021
Q1 		$5.36M Sell
64,975
-4,053
-6% -$388K 0.01% 991
2020
Q4 		$6.28M Buy
69,028
+14,623
+27% +$908K 0.01% 917
2020
Q3 		$2.17M Sell
54,405
-2,660
-5% -$92.9K ﹤0.01% 1293
2020
Q2 		$1.96M Sell
57,065
-19,794
-26% -$590K ﹤0.01% 1349
2020
Q1 		$1.71M Buy
76,859
+220
+0.3% +$5.56K ﹤0.01% 1450
2019
Q4 		$1.5M Buy
+76,639
New +$1.22M ﹤0.01% 1715

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prudential Financial's FATE Position: Q1 2026 in Review

Prudential Financial increased its Fate Therapeutics (FATE) stake by 14% in Q1 2026, buying an estimated $3.86K and bringing the position to 26,330 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

Prudential Financial first reported a position in FATE in Q4 2019 and has held it in 23 quarters since. The position peaked at $6.47M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Prudential Financial held 26,330 shares of Fate Therapeutics worth $31.6K as of Q1 2026.
  • Prudential Financial bought 3,170 Fate Therapeutics shares in Q1 2026, an estimated $3.86K.
  • Fate Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2358 holding.
  • Prudential Financial first reported a position in Fate Therapeutics in Q4 2019 and has held it in 23 quarters since.
  • Prudential Financial's Fate Therapeutics position peaked at $6.47M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.